2015-16 Drake Memorial Library Annual Report

The 2015-2016 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

Drake Memorial Library 2016-17 Annual Report

The 2016-2017 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

2011-2012 Drake Memorial Library Annual Report

The 2011-2012 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Bob Cushman, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

2009-2010 Drake Memorial Library Annual Report

The 2009-2010 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Bob Cushman, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

2012-2013 Drake Memorial Library Annual Report

The 2012-2013 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Bob Cushman, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

2014-15 Drake Memorial Library Annual Report

The 2014-2015 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Bob Cushman, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

2010-2011 Drake Memorial Library Annual Report

The 2010-2011 annual report of Drake Memorial Library of The College at Brockport, as compiled by Mary Jo Orzech, Bob Cushman, Pam O\u27Sullivan and Jennifer Smathers with contributions from the Drake Faculty and Staff

Impact of cyclooxygenase inhibitors in the Women\u27s Health Initiative hormone trials: secondary analysis of a randomized trial

OBJECTIVES: We evaluated the hypothesis that cyclooxygenase (COX) inhibitor use might have counteracted a beneficial effect of postmenopausal hormone therapy, and account for the absence of cardioprotection in the Women\u27s Health Initiative hormone trials. Estrogen increases COX expression, and inhibitors of COX such as nonsteroidal anti-inflammatory agents appear to increase coronary risk, raising the possibility of a clinically important interaction in the trials. DESIGN: The hormone trials were randomized, double-blind, and placebo-controlled. Use of nonsteroidal anti-inflammatory drugs was assessed at baseline and at years 1, 3, and 6. SETTING: The Women\u27s Health Initiative hormone trials were conducted at 40 clinical sites in the United States. PARTICIPANTS: The trials enrolled 27,347 postmenopausal women, aged 50-79 y. INTERVENTIONS: We randomized 16,608 women with intact uterus to conjugated estrogens 0.625 mg with medroxyprogesterone acetate 2.5 mg daily or to placebo, and 10,739 women with prior hysterectomy to conjugated estrogens 0.625 mg daily or placebo. OUTCOME MEASURES: Myocardial infarction, coronary death, and coronary revascularization were ascertained during 5.6 y of follow-up in the estrogen plus progestin trial and 6.8 y of follow-up in the estrogen alone trial. RESULTS: Hazard ratios with 95% confidence intervals were calculated from Cox proportional hazard models stratified by COX inhibitor use. The hazard ratio for myocardial infarction/coronary death with estrogen plus progestin was 1.13 (95% confidence interval 0.68-1.89) among non-users of COX inhibitors, and 1.35 (95% confidence interval 0.86-2.10) among continuous users. The hazard ratio with estrogen alone was 0.92 (95% confidence interval 0.57-1.48) among non-users of COX inhibitors, and 1.08 (95% confidence interval 0.69-1.70) among continuous users. In a second analytic approach, hazard ratios were calculated from Cox models that included hormone trial assignment as well as a time-dependent covariate for medication use, and an interaction term. No significant interaction was identified. CONCLUSIONS: Use of COX inhibitors did not significantly affect the Women\u27s Health Initiative hormone trial results

Religion and Healthy Lifestyle Behaviors Among Postmenopausal Women: the Women\u27s Health Initiative

Worship attendance has been associated with longer survival in prospective cohort studies. A possible explanation is that religious involvement may promote healthier lifestyle choices. Therefore, we examined whether attendance is associated with healthy behaviors, i.e. use of preventive medicine services, non-smoking, moderate drinking, exercising regularly, and with healthy dietary habits. The population included 71,689 post-menopausal women enrolled in the Women\u27s Health Initiative observational study free of chronic diseases at baseline. Attendance and lifestyle behaviors information was collected at baseline using self-administered questionnaires. Healthy behaviors were modeled as a function of attendance using logistic regression. After adjustment for confounders, worship attendance (less than weekly, weekly, and more than weekly vs. never) was positively associated with use of preventive services [OR for mammograms: 1.34 (1.19, 1.51), 1.41 (1.26, 1.57), 1.33 (1.17, 1.52); breast self exams: 1.14 (1.02, 1.27), 1.33 (1.21, 1.48), 1.25 (1.1, 1.43); PAP smears: 1.22 (1.01, 1.47-weekly vs. none)]; non-smoking: [1.41 (1.35, 1.48), 1.76 (1.69, 1.84), 2.27 (2.15, 2.39)]; moderate drinking [1.35 (1.27, 1.45), 1.60 (1.52, 1.7), 2.19 (2.0, 2.4)]; and fiber intake [1.08 (1.03, 1.14), 1.16 (1.11, 1.22), 1.31 (1.23, 1.39), respectively], but not with regular exercise or with lower saturated fat and caloric intake. These findings suggest that worship attendance is associated with certain, but not all, healthy behaviors. Further research is needed to get a deeper understanding of the relationship between religious involvement and healthy lifestyle behaviors and of the inconsistent patterns in this association